EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma

Thomas G Martin, Deepu Madduri, Lida Pacaud, Saad Z Usmani iD

Future Oncology · 2023-11 · 19 (34) · 2297-2311

DOI: 10.2217/fon-2022-1317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Oncology, online erschienen am 27.07.2023. Verfasst von Thomas G Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Global Services, LLC, Janssen Global Services LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Approval in the EU followed for patients with ≥3 prior therapies. At median 28-month follow-up, the pivotal CARTITUDE-1 trial showed a 98% response rate (83% stringent complete response); median progression-free survival had not been reached, and adverse events could be managed with supportive therapy. Cilta-cel efficacy and safety in earlier lines of therapy, and its optimal sequencing in a complex treatment landscape are important areas of investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaReceptors, Chimeric AntigenHumansB-Cell Maturation AntigenImmunotherapy, AdoptiveProgression-Free Survival

Stichwörter der Autor:innen

B-cell maturation antigenCAR-T therapychimeric antigen receptorciltacabtagene autoleucelefficacymultiple myelomarelapsed/refractorysafety

Substanzen

Receptors, Chimeric AntigenB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.
  • Janssen Research & Development, Raritan, NJ 08869, USA.
  • Legend Biotech USA Inc., Somerset, NJ 08873, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

ORCID-Profile: Saad Z Usmani

Förderung

  • Janssen Global Services, LLC
  • Janssen Global Services LLC

Zitieren

APA

Martin, T. G., Madduri, D., Pacaud, L., & Usmani, S. Z. (2023). Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology, 19(34), 2297-2311. https://doi.org/10.2217/fon-2022-1317

Vancouver

Martin TG, Madduri D, Pacaud L, Usmani SZ. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology. 2023;19(34):2297-2311. doi:10.2217/fon-2022-1317

BibTeX
@article{Martin2023,
  author = {Martin, Thomas G and Madduri, Deepu and Pacaud, Lida and Usmani, Saad Z},
  title = {Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma},
  journal = {Future Oncology},
  year = {2023},
  volume = {19},
  number = {34},
  pages = {2297--2311},
  doi = {10.2217/fon-2022-1317}
}
Kostenlos starten →